Medtronic Q3 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $9 billion, representing an 8.7% increase year-over-year and a 6% organic growth, which is a 50 basis point acceleration from the previous quarter.

Adjusted EPS: $1.36, exceeding guidance by $0.03.

Gross Margin: 64.9%, ahead of expectations, with a mix of pricing benefits and cost pressures.

Adjusted Operating Profit: $2.2 billion, resulting in an adjusted operating margin of 24.1%.

Geographic Performance: High single-digit growth in Western Europe, mid-single-digit growth in the U.S. (6% year-over-year), and low single-digit growth in China.

2Strategic Updates and Business Highlights

Cardiovascular Portfolio: 11% year-over-year growth, with Cardiac Ablation Solutions (CAS) growing 80%. The PFA platform is a key driver, with a 200% increase in revenue.

Neuroscience: Grew 3%, with expectations for improvement from the new Stealth AXiS Surgical System, which received FDA clearance.

Diabetes Business: Grew 15% reported and over 8% organic, with strong international performance and new product launches.

Hugo Surgical Robot: Received FDA clearance for urologic procedures, with initial cases performed and positive feedback from surgeons.

New Product Launches: Symplicity for hypertension and Altaviva for urge urinary incontinence are expected to contribute significantly to growth.

3Forward Guidance and Outlook

Fiscal 2026 Guidance: Reiterating organic revenue growth of approximately 5.5% for the year, with expectations for Q4 growth similar to Q3 (around 6%).

EPS Guidance: Maintaining guidance in the range of $5.62 to $5.66, with high single-digit growth anticipated for fiscal year 2027.

Long-term Growth: Strong pipeline and innovation expected to drive sustained growth across various segments.

4Bad News, Challenges, or Points of Concern

Structural Heart Performance: Soft growth in this segment, with competitive pressures noted.

Neuroscience Growth: Below expectations, but anticipated improvements from the Stealth AXiS system.

Tariff Impact: Anticipated $185 million impact on COGS for fiscal 2026, with ongoing pressure from tariffs and a higher tax rate affecting profitability.

Market Development: Challenges in ramping up new product launches and hiring necessary personnel for market expansion, particularly in renal denervation.

5Notable Q&A Insights

CAS Growth Sustainability: Analysts questioned the sustainability of CAS growth post-launch; management expressed confidence in maintaining high growth rates due to strong market positioning and product pipeline.

Market Development for RDN and Altaviva: Management highlighted the importance of building referral networks and consumer demand, with significant increases in website traffic indicating growing interest.

M&A Strategy: Focus on tuck-in acquisitions and venture investments to enhance growth, with a commitment to capital allocation in high-growth areas.

Competitive Landscape: Management acknowledged competitive pressures but emphasized Medtronic's strong product offerings and market position. Overall, Medtronic reported strong financial results and a positive outlook, driven by innovation and strategic initiatives, while also addressing challenges in certain segments and external pressures.